Spectrum Pharmaceuticals — Investor Presentation (January 2020)
26 slides from Spectrum Pharmaceuticals's investor presentation, Jan 13, 2020
Slide 1: Spectrum Pharmaceuticals Investor Presentation January 2020
Spectrum Pharmaceuticals A Biopharmaceutical Company Developing Targeted and Novel Therapies in Oncology Joe Turgeon | President and CEO January 2020 | Investor Presentation
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management’s current bel
Slide 3: Spectrum's Pipeline: Targeted & Novel Medicines
Spectrum’s Pipeline Targeted & Novel Medicines POZIOTINIB ROLONTIS® FIT Platform (eflapegrastim) Program Update in Q1 PDUFA Date of October 24, 2020 Phase 1 Dose Escalation Study 3
Slide 4: Poziotinib
Poziotinib Tyrosine Kinase Inhibitor targeting mutations in lung cancer Results from ZENITH20 cohort 2 in mid-2020 Results from ZENITH20 cohort 3 in 2020 Program update in Q1 4
Slide 5: Unique Structure Provides Irreversible Binding
Unique Structure Provides Irreversible Binding Poziotinib Even with the restricted binding pocket of exon 20 mutations, preclinical studies have shown that poziotinib is able to overcome steric hindrance allowing for irreversible binding 5
Slide 6: ZENITH Cohort Topline Results
ZENITH 20 Cohort 1 Topline Results Topline Result Pre-specified primary endpoint not met Patients 115 previously treated non- small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations Objective Rate of Response 14.8% (CI: 8.9% - 22.6%) Disease Control Rate 68.7% Median Duration o
Slide 7: ZENITH Cohort Waterfall Plot
ZENITH 20 Cohort 1 Waterfall Plot Best Percent Change from BaselineF inigu Sumre 14.2 .of4 Longest Diameter by Treatment Group Percent Change from Baseline in Sum of Longest Diameter by Treatment Group- Waterfall Plots r e t e 100 m a i 90 D t s e 70 g n o L 50 f o m u 30 S n i 10 e n i l e -10 s a
Slide 8: ZENITH20: Spectrum Sponsored Study
ZENITH20: Spectrum Sponsored Study Cohort 2 (N=87) Previously treated NSCLC with HER2 exon 20 insertions ➢ Primary ➢ Objective Response Rate Cohort 3 ➢ Secondary (N=70) First-line NSCLC with EGFR exon ➢ Disease Control Rate 20 insertions ➢ Duration of Response ➢ Safety & Tolerability Cohort 4 (N=70)
Slide 9: ZENITH20: Exploratory Cohorts Enrolling Patients
ZENITH20: Exploratory Cohorts Enrolling Patients Cohort 5 ▪ Cohort 5 allows access to poziotinib and (N=180) gathers additional data at a lower dosage EGFR or HER2 Exon 20 insertions ▪ Cohort 6 is enrolling NSCLC patients with Cohort 6 EGFR mutations who have progressive (N=30) disease on first-line
Slide 10: Exon Mutations in Various Tumor Types
Exon 20 Mutations in Various Tumor Types Prevalence of Exon20 NSCLC in Key Markets Prevalence of Exon20 In Other Tumors Exon 20 Exon 20 Total Number of Exon- Total Exon 20 (non-Lung) Region Mutation Region Mutation Frequency Frequency (%) 20 NSCLC Patients/year Patients/year (%) EGFR 2.1% US 3.6% 7,
Slide 11: ROLONTIS BLA Accepted with PDUFA Date of Oct 24th 2020
ROLONTIS® (eflapegrastim) BLA has been accepted with a PDUFA of Oct 24th 2020 11
Slide 12: ROLONTIS is a Novel Product with a Unique Molecular Structure
ROLONTIS is a Novel Product with a Unique Molecular Structure 12
Slide 13: Robust Data Set Features Head to Head Data vs Neulasta
Robust Data Set Features Head to Head Data vs Neulasta Met Met All Similar AE 643 Primary Secondary Patients in Two Profile Phase 3 Trials Endpoint* Endpoints ADVANCE (-301) RECOVER (-302) ROLONTIS Pegfilgrastim ROLONTIS Pegfilgrastim N=196 N=210 N=118 N=119 DSN (days) 0.20 (0.503) 0.35 (0.683) 0.31
Slide 14: Integrated Phase 3 Results Presented at ASCO 2019
Integrated Phase 3 Results Presented at ASCO 2019 Incidence of Severe Neutropenia from Two Phase 3 ROLONTIS Trials 14
Slide 15: Long Acting G-CSF Market Presents a Compelling Opportunity
Long Acting G-CSF Market Presents a Compelling Opportunity ▪ >$3B total US market value Market Size ▪ Rational pricing behavior among competitors ▪ Unique reimbursement for novel products is a competitive advantage Reimbursement ▪ Value based care creates additional complexity in Dynamics customer’s
Slide 16: Pricing and Market Landscape
Pricing and Market Landscape Estimated Long Acting G-CSF Market Share: WAC $6,231 Aug 2019 Neulasta 76% ASP $4,275 Biosimilar’s ASPs are 5-13% below Neulasta ASP Udenyca, 18% Fulphila, 6% Neulasta Pricing: Q1 2020 16
Slide 17: Focused Interferon Therapeutics Platform
Focused Interferon Therapeutics Platform ▪ IFNa is an approved treatment for cancer ▪ But systemic IFNa therapy has limitations due to dose limiting toxicity ▪ Focused IFNa Therapeutics (FIT) Technology seeks to overcome the toxicity while maintaining efficacy FIT Platform ▪ By attaching IFNa to an
Slide 18: FIT – Fusion of Interferon and Targeted Antibodies
FIT – Fusion of Interferon (IFNα) and Targeted Antibodies ▪ Unaltered binding to Fc receptor Proteolysis-resistant short peptide LINKER ▪ Growth inhibition ▪ Turn cold tumors into HOT Interferon ▪ Direct Apoptosis (IFNa) 18
Slide 19: Mechanism of Action
Mechanism of Action Tumor Cells with Antibody Target Normal Cells without Antibody Target Antibody Antibody does not binds target bind cell surface antigen 1 IFN Target antigen IFN Target antigen 2 3 IFN binds Ab-IFN binds IFN-R poorly to IFN-R IFN-R No IFN-R signaling signaling Apoptosis/Growth arr
Slide 20: Lead Asset in Phase 1 Study
Lead Asset in Phase 1 Study ▪ Phase 1, Open-Label, Dose-Escalation Study in Subjects with Refractory Non-Hodgkin Lymphoma ⁻ Evaluate the Safety, Tolerability, and PK of Multiple IV Doses with Weekly Administration ⁻ Planned for up to 20 subject at maximum tolerated dose ▪ Primary Outcome Measures ⁻
Slide 21: Strong Financial Position
Strong Financial Position Cash used in Operating Activities $45 $40 $40 $36 $35 $30 $27 Cash & Marketable $25 Securities balance at 9/30/19 $20 was $252 million $15 $10 $5 $0 Q1 2019 Q2 2019 Q3 2019 $ in millions 21
Slide 22: Spectrum's Pipeline: Targeted & Novel Medicines
Spectrum’s Pipeline Targeted & Novel Medicines POZIOTINIB ROLONTIS® FIT Platform (eflapegrastim) Program Update in Q1 PDUFA Date of October 24, 2020 Phase 1 Dose Escalation Study 22
Slide 23: Non-GAAP Financial Measures (from Continuing Operations)
Non-GAAP Financial Measures (from Continuing Operations) In this press release, Spectrum reports certain historical results that have not been prepared in accordance with generally accepted accounting principles (GAAP), including non-GAAP selling, general and administrative expenses, non-GAAP resear
Slide 24: Non-GAAP net loss footnotes
(3) Non-GAAP net loss (from continuing operations): These amounts reflect all non-GAAP adjustments described in (1) through (2) above, plus other non-cash and/or non-recurring items, including: (i) adjustments to reverse the impact of income taxes; (ii) reversal of foreign exchange gains and losses
Slide 25: Condensed Consolidated Statements of Operations
‘Revenues Operating costs and expenses: Selling, general and administrative 46,308 Research and development 56,035 ‘Total operating costs and expenses 102,343 91,389 ee ee ne enone G02) sana) 402,34) (91,389) Other income (expanse): Interest income (expense), net 1,321 an 4076 (484) (Other income (e
Slide 26: Condensed Consolidated Balance Sheets
26 ‘SPECTRUM PHARMACEUTICALS, INC. Condensed Consolidated Balance Sheets Gin thousands, expect per share and par value amounts) (Unaudited) (Current assets: (Cash and cash equivalents Restricted cash ‘Marketable securities Accounts receivable, net of allowance for doubtful accounts of $67 and $67, r
Spectrum Pharmaceuticals — Investor Presentation (January 2020) on 6ix